Article
Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.
International journal of molecular sciences - 30 Aug 2024
Leifheit Malia E, Johnson Gunnar, Kuzel Timothy M, Schneider Jeffrey R, Barker Edward, Yun Hyun D, Ustun Celalettin, Goldufsky Josef W, Gupta Kajal, Marzo Amanda L
Abstract excerpt
FMS-like tyrosine kinase 3 (FLT3) mutations are genetic changes found in approximately thirty percent of patients with acute myeloid leukemia (AML). FLT3 mutations in AML represent a challenging clinical scenario characterized by a high rate of relapse, even after allogeneic hematopoietic stem ce...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Leukemia, Myeloid, Acute
- Protein Kinase Inhibitors
- Antineoplastic Combined Chemotherapy Protocols
- Pyrazines
- TOR Serine-Threonine Kinases
- Animals
- Mutation
- Signal Transduction
- Aniline Compounds